QTTB Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 40.00%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $141,163.08

Q32 Bio Insider Trading History Chart

Q32 Bio Share Price & Price History

^$3.62

▲ +0.05 (1.40%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

Q32 Bio Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/2/2025	Jodie Pope Morrison	CEO	Sell	22,506	$3.46	$77,870.76	99,000
12/2/2025	Lee Kalowski	CFO	Sell	9,072	$3.46	$31,389.12	39,938
8/26/2025	Jodie Pope Morrison	CEO	Sell	10,494	$1.80	$18,889.20	121,506
8/26/2025	Lee Kalowski	CFO	Sell	4,240	$1.80	$7,632.00	49,010
8/26/2025	Shelia M Violette	Insider	Sell	2,990	$1.80	$5,382.00	58,384
3/25/2024	Paul Alloway	Insider	Sell	268	$24.21	$6,488.28	2,596

SEC Filings (Institutional Ownership Changes) for Q32 Bio (NASDAQ:QTTB)

31.32% of Q32 Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Q32 Bio Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/17/2025	Millennium Management LLC	104,772	$0.21M	0.0%	-19.6%	0.852%
11/14/2025	Two Sigma Investments LP	31,506	$62K	0.0%	N/A	0.258%
11/10/2025	Monaco Asset Management SAM	311,137	$0.62M	0.0%	-47.4%	2.551%
8/14/2025	Jane Street Group LLC	46,635	$69K	0.0%	N/A	0.382%
8/13/2025	Marshall Wace LLP	16,928	$25K	0.0%	N/A	0.139%
8/8/2025	Geode Capital Management LLC	61,599	$92K	0.0%	-55.2%	0.505%
8/7/2025	Monaco Asset Management SAM	591,937	$0.88M	0.2%	+17.1%	4.852%
6/27/2025	Goldman Sachs Group Inc.	44,373	$73K	0.0%	+140.9%	0.364%
5/21/2025	Acadian Asset Management LLC	31,138	$50K	0.0%	N/A	0.255%
5/16/2025	Goldman Sachs Group Inc.	44,373	$73K	0.0%	+140.9%	0.364%
5/16/2025	AQR Capital Management LLC	41,302	$68K	0.0%	N/A	0.339%
5/12/2025	Nuveen LLC	55,886	$92K	0.0%	N/A	0.458%
5/8/2025	Monaco Asset Management SAM	505,451	$0.83M	0.2%	-12.1%	4.144%
2/19/2025	Public Employees Retirement System of Ohio	7,540	$26K	0.0%	N/A	0.062%
2/17/2025	Squarepoint Ops LLC	19,009	$65K	0.0%	N/A	0.156%
2/17/2025	Two Sigma Investments LP	53,175	$0.18M	0.0%	N/A	0.437%
2/17/2025	Trustees of Columbia University in the City of New York	133,903	$0.46M	0.1%	N/A	1.099%
2/17/2025	Sanofi	244,083	$0.84M	0.5%	N/A	2.004%
2/17/2025	Millennium Management LLC	10,725	$37K	0.0%	-89.3%	0.088%
2/17/2025	Jacobs Levy Equity Management Inc.	34,844	$0.12M	0.0%	N/A	0.286%
2/17/2025	Deutsche Bank AG	25,018	$86K	0.0%	+699.8%	0.205%
2/17/2025	Cubist Systematic Strategies LLC	12,249	$42K	0.0%	N/A	0.101%
2/17/2025	Ameriprise Financial Inc.	15,548	$53K	0.0%	N/A	0.128%
2/17/2025	ArrowMark Colorado Holdings LLC	81,482	$0.28M	0.0%	N/A	0.669%
2/17/2025	Acorn Capital Advisors LLC	803,425	$2.76M	1.5%	N/A	6.596%
2/13/2025	Mariner LLC	121,427	$0.42M	0.0%	N/A	0.997%
2/13/2025	Townsquare Capital LLC	17,466	$60K	0.0%	N/A	0.143%
2/13/2025	Raymond James Financial Inc.	10,746	$37K	0.0%	N/A	0.088%
2/11/2025	AXQ Capital LP	10,581	$36K	0.0%	N/A	0.087%
2/10/2025	Monaco Asset Management SAM	574,816	$1.98M	0.3%	N/A	4.719%
2/6/2025	Raymond James Financial Inc.	10,746	$37K	0.0%	N/A	0.088%
2/3/2025	Hussman Strategic Advisors Inc.	10,500	$36K	0.0%	N/A	0.086%
1/30/2025	Rhumbline Advisers	105,544	$0.36M	0.0%	+1,164.3%	0.867%
1/29/2025	Savant Capital LLC	15,281	$53K	0.0%	N/A	0.125%
1/27/2025	Bleakley Financial Group LLC	43,360	$0.15M	0.0%	N/A	0.356%
1/22/2025	Drive Wealth Management LLC	10,928	$38K	0.0%	N/A	0.090%
11/27/2024	Franklin Resources Inc.	4,857	$0.23M	0.0%	N/A	0.040%
11/19/2024	Barclays PLC	10,443	$0.47M	0.0%	+105.2%	0.086%
11/16/2024	Geode Capital Management LLC	131,768	$5.88M	0.0%	+22.4%	1.082%
11/15/2024	Barclays PLC	10,443	$0.47M	0.0%	+105.2%	0.086%
11/15/2024	Jane Street Group LLC	16,437	$0.73M	0.0%	N/A	0.135%
11/15/2024	State Street Corp	110,164	$4.92M	0.0%	+35.5%	0.904%
11/15/2024	Point72 Asset Management L.P.	76,685	$3.42M	0.0%	N/A	0.630%
11/14/2024	Eventide Asset Management LLC	190,000	$8.48M	0.1%	N/A	1.560%
11/14/2024	MetLife Investment Management LLC	3,563	$0.16M	0.0%	N/A	0.029%
11/13/2024	BNP Paribas Financial Markets	1,298	$58K	0.0%	+199.1%	0.011%
11/13/2024	FMR LLC	426,302	$19.02M	0.0%	+137.3%	3.500%
10/23/2024	Values First Advisors Inc.	741	$33K	0.0%	N/A	0.006%
8/13/2024	Ensign Peak Advisors Inc	64,481	$1.16M	0.0%	+150.6%	0.540%
8/9/2024	Renaissance Technologies LLC	14,764	$0.27M	0.0%	N/A	0.124%
8/9/2024	Harvard Management Co. Inc.	162,965	$2.93M	0.2%	N/A	1.365%
8/1/2024	Rhumbline Advisers	7,658	$0.14M	0.0%	+11,681.5%	0.064%
7/26/2024	Bank of New York Mellon Corp	17,569	$0.32M	0.0%	N/A	0.147%
5/17/2024	Ikarian Capital LLC	22,335	$0.38M	0.0%	N/A	0.685%
5/15/2024	ARCH Venture Management LLC	320,482	$5.46M	6.5%	N/A	9.831%
5/15/2024	Affinity Asset Advisors LLC	27,777	$0.47M	0.1%	N/A	0.852%
5/14/2024	Platinum Investment Management Ltd.	109,964	$1.87M	0.1%	N/A	3.373%
5/10/2024	Acadian Asset Management LLC	3,695	$62K	0.0%	N/A	0.113%
5/10/2024	Vanguard Group Inc.	107,752	$1.84M	0.0%	N/A	3.305%
5/6/2024	Atlas Venture Life Science Advisors LLC	2,092,106	$35.65M	3.3%	N/A	64.254%
5/3/2024	Carlyle Group Inc.	1,102,741	$18.07M	1.1%	N/A	33.826%
4/23/2024	BML Capital Management LLC	24,894	$0.42M	0.3%	N/A	0.764%
4/22/2024	Vivo Capital LLC	370,068	$6.31M	0.5%	N/A	11.366%

Data available starting January 2016

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Today's Range

Now: $3.62

$3.25

$3.75

50 Day Range

MA: $2.64

$1.89

$3.95

52 Week Range

Now: $3.62

$1.35

$28.06

Volume

892,817 shs

Average Volume

8,886,970 shs

Market Capitalization

$44.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Who are the company insiders with the largest holdings of Q32 Bio?: Q32 Bio's top insider investors include:
Jodie Pope Morrison (CEO)
Shelia M Violette (Insider)
Lee Kalowski (CFO)
Paul Alloway (Insider)
Learn More about top insider investors at Q32 Bio.
Who are the major institutional investors of Q32 Bio?: Q32 Bio's top institutional investors include:
Monaco Asset Management SAM — 2.55%
Millennium Management LLC — 0.85%
Two Sigma Investments LP — 0.26%
Learn More about top institutional investors of Q32 Bio stock.
Which major investors are selling Q32 Bio stock?: Within the previous quarter, QTTB stock was sold by these institutional investors:
Monaco Asset Management SAM
Millennium Management LLC
In the previous year, company insiders that have sold Q32 Bio company stock include:
Jodie Pope Morrison (CEO)
Shelia M Violette (Insider)
Lee Kalowski (CFO)
Learn More investors selling Q32 Bio stock.
Which major investors are buying Q32 Bio stock?: During the previous quarter, QTTB stock was acquired by institutional investors including:
Two Sigma Investments LP